EP1355881A2 - An improved process for preparing pure ondansetron hydrochloride dihydrate - Google Patents

An improved process for preparing pure ondansetron hydrochloride dihydrate

Info

Publication number
EP1355881A2
EP1355881A2 EP02703115A EP02703115A EP1355881A2 EP 1355881 A2 EP1355881 A2 EP 1355881A2 EP 02703115 A EP02703115 A EP 02703115A EP 02703115 A EP02703115 A EP 02703115A EP 1355881 A2 EP1355881 A2 EP 1355881A2
Authority
EP
European Patent Office
Prior art keywords
process according
solution
ondansetron
methyl
hydrochloride dihydrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02703115A
Other languages
German (de)
French (fr)
Other versions
EP1355881A4 (en
Inventor
Ramy Lidor Hadas
Eliezer Bachar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Publication of EP1355881A2 publication Critical patent/EP1355881A2/en
Publication of EP1355881A4 publication Critical patent/EP1355881A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/86—Carbazoles; Hydrogenated carbazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Definitions

  • the present invention relates to an improved process for preparing dimethylamino-methyl-carbazolone.
  • the present invention relates to an improved process for preparing ondansetron base.
  • the present invention also relates to an improved process for recrystallizing ondansetron hydrochloride dihydrate to obtain pure ondansetron hydrochloride dihydrate.
  • Ondansetron also known as l,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-lH- imidazol-1-yl) methyl] -4H-carbazol-4-one is a potent and highly selective serotonin (5-HT 3 , 5-hydroxytrptamine receptor 3) antagonist and has the following formula:
  • Ondansetron is currently available as an anti-emetic agent, particularly in cancer chemotherapy, and in some other uses such as anti-depressive, anti- migraine and anti-psychotic. It is commonly used in the alleviation of cognitive disorders as in Alzheimer disease, in treatment of rhinitis, psychiatric disorders and for increased vigilance and for control of dependence on narcotics.
  • An object of the present invention is to meet a need in the art for a high purity (i.e., at least about 99.0%) and improved color.
  • Another object of the present invention is to prepare pure ondansetron hydrochloride dihydrate substantially free of any impurities and by-product such as l,2,3,9-tetrahydro-9-methyl-3-methylene-4H-carbazol-4-one (e.g., the exo- methylene by-product).
  • Another object of the present invention is to prepare ondansetron hydrochloride dihydrate that has a purity of at least about 99.0%.
  • the ondansetron hydrochloride dihydrate has a purity of at least about 99.5%.
  • the ondansetron hydrochloride dihydrate has a purity of at least about 99.9%.
  • Another object of the present invention is to provide a process for preparing dimethylamino-methyl-carbazolone, the process comprising the steps of: a) preparing a solution of methyl-carbazolone; b) heating the solution in the presence of dimethylamino hydrochloride and paraformaldehye; c) basifying the solution to form a precipitate; d) separating the precipitate from the solution to obtain dimethylamino- methyl-carbazolone; and e) drying the dimethylamino-methyl-carbazolone.
  • Another object of the present invention is a process for preparing ondansetron base, the process comprising the steps of: a) preparing a solution of methyl-imidzole and dimethylamino-methyl- carbazolone; b) heating the solution; c) removing a precipitate containing ondansetron base; d) washing the precipitate; and e) drying the precipitate to obtain pure ondansetron base.
  • step e) is followed by recrystallizing the ondansetron base in the presence of activated carbon and methanol.
  • Another object of the present invention is a process for preparing ondansetron hydrochloride dihydrate, the process comprising the steps of: a) preparing a solution of ondansetron base; b) acidifying the solution with hydrogen chloride to form a precipitate; c) washing the precipiate; and d) crystallizing ondansetron hydrochloride dihydrate.
  • exo-methylene by-product refers to 1,2,3,9- tetrahydro-9-methyl-3-methylene-4H-carbazol-4-one. It represents one of the main impurity in ondansetron preparation. Another impurity in ondansetron preparation is dimeric exo-methylene by-product.
  • % refers to % wt.
  • pure ondansetron refers to ondansetron that is substantially free of exo-methylene by-product and has a high purity of at least about 99.0%.
  • hydrogen chloride refers to either a gaseous hydrogen chloride or a solution of hydrogen chloride gas in water.
  • equivalent refers to molar equivalent.
  • vacuum distillation refers to the separation of solids from liquids by passing the mixture through a vacuum filter.
  • the term "reflux” refers to during a chemical process, part of the product stream maybe returned to the process to assist in giving increased conversion or recovery, as in distillation or liquid-liquid extraction.
  • filter cake refers to a concentrated solid or semisolid material that is separated from a liquid and remains on the filter after pressure filtration.
  • the present invention is an improved method of preparing a pure ondansetron hydrochloride dihydrate with purity at least 99.0%. More preferably, the ondansetron hydrochloride dihydrate purity is at least 99.5%. Most preferably, the ondansetron hydrochloride dihydrate purity is at least 99.9%.
  • the present invention provides an improved method of preparing dimethylamino-methyl-carbazolone.
  • the present invention further provides an improved method of preparing ondansetron base.
  • the present invention further provides an improved method of preparing pure ondansetron hydrochloride dihydrate.
  • the present invention provides a process for preparing dimethyl amino- methyl-carbazolone comprising the steps of: a) preparing a solution of methyl-carbazolone having the formula:
  • the solution is heated in the presence of dimethylamine hydrochloride and paraformaldehyde in an organic solvent.
  • the organic solvent is acetic acid.
  • one equivalent methyl-carbazolone is refluxed with about 1.1 to about 1.5 equivalents of dimethylamine-hydrochloride and paraformaldehyde. Most preferably, one equivalent methyl-carbazolone is refluxed with about 1.2 equivalents of dimethylamine-hydrochloride and paraformaldehyde.
  • formaldehyde can be used to substitute for paraformaldehyde in the reflux reaction.
  • one equivalent methyl-carbazolone is refluxed with about 4 to about 16 volumes of acetic acid.
  • one equivalent methyl- carbazolone is refluxed with about 4 volumes of acetic acid.
  • the heating step is performed at a temperature of about 70°C to about 100°C. Most preferably, the heating step is performed at a temperature of about 80° to about 90° C.
  • the heating step is performed for about 6 to about 24 hours.
  • the heating step is performed for about 6 to about 12 hours.
  • the separating step is performed using filtration.
  • the heating step is performed without the use of vacuum distillation or extraction.
  • the heating step performed in the absence of vacuum distillation or extraction consistently yields a better pure dimethylamino-methyl- carbazolone.
  • water is added at the basifying step thereafter rendering the solution basic by about 45 % sodium hydroxide (NaOH) to a pH range of about 13 to about 14.
  • the basifying step is performed in the presence of celite (10%), filter and dry.
  • the dry cake is dissolved in acetone.
  • the dissolved cake is treated with activated carbon and hydrogen chloride to precipitate dimethylamino-methyl-carbazolone.
  • the present invention provides a process for the synthesis of ondansetron base comprising the steps of: a) preparing a solution of methyl-imidazole and dimethylamino-methyl- carbazolone of the formula
  • the present invention further provides a process for the synthesis of substantially pure ondansetron base, further comprising the steps of: recrystallizing in the presence of activated carbon and methanol.
  • methyl-imidazole and dimethylamino-methyl-carbazolone about 4 to about 6 equivalents methyl- imidazole is preferably added to one equivalent dimethylamino-methyl- carbazolone. Most preferably, about 5 equivalents of methyl-imidazole is added to one equivalent dimethylamino-methyl-carbazolone.
  • the preparation step is performed in the presence of 10% celite.
  • the present invention provides a process for preparing ondansetron base further comprising (after step e) a step of recrystallizing ondansetron base in the presence of activated carbon and methanol.
  • the present invention provides an improved method of preparing a pure ondansetron hydrochloride dihydrate. Specifically, the preparation involves crystallization of ondansetron hydrochloride dihydrate from ondansetron base with water and activated carbon and in the absence of an organic solvent.
  • the present invention provides a method of crystallization of ondansetron hydrochloride dihydrate comprising the steps of: a) preparing a solution of ondansetron base; b) acidifying the solution with hydrogen chloride to form a precipitate; c) washing the precipitate; and d) crystallizing pure ondansetron hydrochloride dihydrate.
  • the solution preparation step is achieved by adding about 3 to about 7 volumes of water to ondansetron base. Most preferably, the solution preparation step is achieved by adding about 5 volumes of water to ondanseton base.
  • the acidifying step is achieved by adding hydrochloric acid.
  • the acidifying step is achieved at a pH about 1 to about 4. Most preferably, the acidifying step is achieved at a pH about 3.
  • the washing step is achieved by using isopropanol.
  • isopropanol Preferably, about 5 to about 15ml of isopropanol is used to wash the precipitates. Most preferably, about 10 ml of isopropanol is used to wash the precipitates.
  • the crystallizing step is performed in the presence of activated carbon.
  • the activated carbon is selected from the group consisting of SX-2, CA-1, CXV, and SX-1.
  • the reaction was kept at about 80 ⁇ 2°C during 12 hours, then 540 ml of water and 4.5 gram of highflow are introduced into the reactor, the batch was cooled to about 10°C and rendered basic with about 45% NaOH to about pH 13 to about 14 while the batch temperature did not exceed about 25°C.
  • the crude product was treated with 3.3 gram activated carbon type SX-1 (by NORIT) in 990 ml acetone, filtered, cooled to about 25°C and hydrochloric acid was bubbled through the acetone solution until pH was about 3, the batch was cooled to about 0 to about 5° C, kept at this temperature for half an hour, filtered, washed with about 20 ml acetone and dried in an oven at about 50°C until constant weight to give 49.6 gram dimethylamino-methyl-carbozolone-HCl.
  • Ondansetron-HCl-2H 2 O was crystallized twice from 1 :4 w/v water and about 10% w/w activated carbon type SX-1 (by NORIT) at about 95°C during half an hour, filtered (hot filtration), washed with 1 volume of hot water, cooled to about 5°C and kept at this temperature for about 1 hour. The crystals was collected, washed with about 10 ml cold isopropanol and dried to give pure ondansetron-HCl-2H O.
  • the obtained pure ondansetron hydrochloride dihydrate was determined by HPLC to be at least greater than 99.0%.
  • the obtained pure ondansetron hydrochloride dihydrate contained less than 0.01% exo-methylene byproduct or undetectable.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Otolaryngology (AREA)
  • Anesthesiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)

Abstract

An improved method for preparing dimethylamino-methyl-carbazolone and ondansetron base. A recrystallization process for preparing pure ondansetron hydrochloride dihydrate with a purity of at least 99.0% is also disclosed.

Description

AN IMPROVED PROCESS FOR PREPARING PURE ONDANSETRON HYDROCHLORIDE DIHYDRATE
CROSS REFERENCE TO RELATED APPLICATION This application claims the benefit of Provisional Application Serial No.
60/261,051, filed January 11, 2001, the disclosure of which is incorporated by reference in its entirety herein.
FIELD OF THE INVENTION The present invention relates to an improved process for preparing dimethylamino-methyl-carbazolone. The present invention relates to an improved process for preparing ondansetron base. The present invention also relates to an improved process for recrystallizing ondansetron hydrochloride dihydrate to obtain pure ondansetron hydrochloride dihydrate.
BACKGROUND OF THE INVENTION
Ondansetron, also known as l,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-lH- imidazol-1-yl) methyl] -4H-carbazol-4-one is a potent and highly selective serotonin (5-HT3, 5-hydroxytrptamine receptor 3) antagonist and has the following formula:
Ondansetron is currently available as an anti-emetic agent, particularly in cancer chemotherapy, and in some other uses such as anti-depressive, anti- migraine and anti-psychotic. It is commonly used in the alleviation of cognitive disorders as in Alzheimer disease, in treatment of rhinitis, psychiatric disorders and for increased vigilance and for control of dependence on narcotics.
U.S. Patent No. 4,695,578, assigned to the Glaxo Group Limited, describes a process of preparing ondansetron and uses thereof. However, ondansetron prepared according to said process contains impurities and by-products such as l,2,3,9-tetrahydro-9-methyl-3-methylene-4H-carbazol-4-one.
There is a continuing need for improving the method of preparing ondansetron with high purity that meets the standard for clinical uses.
OBJECTS AND SUMMARY OF THE INVENTION
The known methods of preparing ondansetron do not achieve a pharmaceutically describe high purity and color. An object of the present invention is to meet a need in the art for a high purity (i.e., at least about 99.0%) and improved color.
Another object of the present invention is to prepare pure ondansetron hydrochloride dihydrate substantially free of any impurities and by-product such as l,2,3,9-tetrahydro-9-methyl-3-methylene-4H-carbazol-4-one (e.g., the exo- methylene by-product).
Another object of the present invention is to prepare ondansetron hydrochloride dihydrate that has a purity of at least about 99.0%. Preferably, the ondansetron hydrochloride dihydrate has a purity of at least about 99.5%. Most preferably, the ondansetron hydrochloride dihydrate has a purity of at least about 99.9%.
Another object of the present invention is to provide a process for preparing dimethylamino-methyl-carbazolone, the process comprising the steps of: a) preparing a solution of methyl-carbazolone; b) heating the solution in the presence of dimethylamino hydrochloride and paraformaldehye; c) basifying the solution to form a precipitate; d) separating the precipitate from the solution to obtain dimethylamino- methyl-carbazolone; and e) drying the dimethylamino-methyl-carbazolone. Another object of the present invention is a process for preparing ondansetron base, the process comprising the steps of: a) preparing a solution of methyl-imidzole and dimethylamino-methyl- carbazolone; b) heating the solution; c) removing a precipitate containing ondansetron base; d) washing the precipitate; and e) drying the precipitate to obtain pure ondansetron base.
Preferably, step e) is followed by recrystallizing the ondansetron base in the presence of activated carbon and methanol.
Another object of the present invention is a process for preparing ondansetron hydrochloride dihydrate, the process comprising the steps of: a) preparing a solution of ondansetron base; b) acidifying the solution with hydrogen chloride to form a precipitate; c) washing the precipiate; and d) crystallizing ondansetron hydrochloride dihydrate.
DETAILED DESCRIPTION OF THE INVENTION
As used herein, the term "exo-methylene by-product" refers to 1,2,3,9- tetrahydro-9-methyl-3-methylene-4H-carbazol-4-one. It represents one of the main impurity in ondansetron preparation. Another impurity in ondansetron preparation is dimeric exo-methylene by-product.
Unless otherwise specified, "%" refers to % wt.
As used herein, the term "pure ondansetron" refers to ondansetron that is substantially free of exo-methylene by-product and has a high purity of at least about 99.0%.
As used herein, the term "hydrogen chloride" refers to either a gaseous hydrogen chloride or a solution of hydrogen chloride gas in water. As used herein, the term "equivalent" refers to molar equivalent.
As used herein, the term "vacuum distillation" refers to the separation of solids from liquids by passing the mixture through a vacuum filter.
As used herein, the term "reflux" refers to during a chemical process, part of the product stream maybe returned to the process to assist in giving increased conversion or recovery, as in distillation or liquid-liquid extraction.
As used herein, the term "filter cake" refers to a concentrated solid or semisolid material that is separated from a liquid and remains on the filter after pressure filtration.
The present invention is an improved method of preparing a pure ondansetron hydrochloride dihydrate with purity at least 99.0%. More preferably, the ondansetron hydrochloride dihydrate purity is at least 99.5%. Most preferably, the ondansetron hydrochloride dihydrate purity is at least 99.9%.
The present invention provides an improved method of preparing dimethylamino-methyl-carbazolone. The present invention further provides an improved method of preparing ondansetron base. The present invention further provides an improved method of preparing pure ondansetron hydrochloride dihydrate.
Preparation of Dimethylamino-Methyl-Carbazolone
The present invention provides a process for preparing dimethyl amino- methyl-carbazolone comprising the steps of: a) preparing a solution of methyl-carbazolone having the formula:
alkyl)
b) heating the solution in the presence of dimethylamino hydrochloride and paraformaldehyde; c) basifying the solution to form a precipitate; d) separating the precipitate from the solution to obtain dimethylamino- methyl-carbazolone; and e)drying the dimethylamino-methyl-carbazolone.
During the heating step, the solution is heated in the presence of dimethylamine hydrochloride and paraformaldehyde in an organic solvent. Preferably, the organic solvent is acetic acid.
Preferably, one equivalent methyl-carbazolone is refluxed with about 1.1 to about 1.5 equivalents of dimethylamine-hydrochloride and paraformaldehyde. Most preferably, one equivalent methyl-carbazolone is refluxed with about 1.2 equivalents of dimethylamine-hydrochloride and paraformaldehyde. During the heating step, formaldehyde can be used to substitute for paraformaldehyde in the reflux reaction.
Preferably, one equivalent methyl-carbazolone is refluxed with about 4 to about 16 volumes of acetic acid. Most preferably, one equivalent methyl- carbazolone is refluxed with about 4 volumes of acetic acid.
Preferably, the heating step is performed at a temperature of about 70°C to about 100°C. Most preferably, the heating step is performed at a temperature of about 80° to about 90° C.
Preferably, the heating step is performed for about 6 to about 24 hours.
Most preferably, the heating step is performed for about 6 to about 12 hours.
Preferably, the separating step is performed using filtration.
Preferably, the heating step is performed without the use of vacuum distillation or extraction. The heating step performed in the absence of vacuum distillation or extraction consistently yields a better pure dimethylamino-methyl- carbazolone.
The present invention also provides a process of preparing pure dimethylamino-methyl-carbazolone further comprises dissolving the filter cake in acetone and treating with activated carbon and hydrogen chloride.
Preferably, water is added at the basifying step thereafter rendering the solution basic by about 45 % sodium hydroxide (NaOH) to a pH range of about 13 to about 14. Preferably, the basifying step is performed in the presence of celite (10%), filter and dry.
Preferably, the dry cake is dissolved in acetone. Preferably, the dissolved cake is treated with activated carbon and hydrogen chloride to precipitate dimethylamino-methyl-carbazolone.
Preparation of Ondansetron Base The present invention provides a process for the synthesis of ondansetron base comprising the steps of: a) preparing a solution of methyl-imidazole and dimethylamino-methyl- carbazolone of the formula
c ι-4, alkyl)
b) heating the solution; c) removing a precipitate containing containing ondasetron base from the solution; d) washing the precipitate; e) drying precipitate to obtain ondansetron base. The present invention further provides a process for the synthesis of substantially pure ondansetron base, further comprising the steps of: recrystallizing in the presence of activated carbon and methanol.
During the solution preparation step of methyl-imidazole and dimethylamino-methyl-carbazolone, about 4 to about 6 equivalents methyl- imidazole is preferably added to one equivalent dimethylamino-methyl- carbazolone. Most preferably, about 5 equivalents of methyl-imidazole is added to one equivalent dimethylamino-methyl-carbazolone.
Preferably, the preparation step is performed in the presence of 10% celite.
Preferably, the present invention provides a process for preparing ondansetron base further comprising (after step e) a step of recrystallizing ondansetron base in the presence of activated carbon and methanol.
Crystallization to Prepare Pure Ondansetron Hydrochloride Dihydrate The present invention provides an improved method of preparing a pure ondansetron hydrochloride dihydrate. Specifically, the preparation involves crystallization of ondansetron hydrochloride dihydrate from ondansetron base with water and activated carbon and in the absence of an organic solvent.
The crystallization process of the present invention greatly increases the purity of ondansetron hydrochloride dihydrate and dramatically lowers the content of the exo-methylene by-product impurity. Preferably, the crystallization step is performed 1-3 times. Most preferably, the crystallization step is performed two times.
The present invention provides a method of crystallization of ondansetron hydrochloride dihydrate comprising the steps of: a) preparing a solution of ondansetron base; b) acidifying the solution with hydrogen chloride to form a precipitate; c) washing the precipitate; and d) crystallizing pure ondansetron hydrochloride dihydrate.
Preferably, the solution preparation step is achieved by adding about 3 to about 7 volumes of water to ondansetron base. Most preferably, the solution preparation step is achieved by adding about 5 volumes of water to ondanseton base.
Preferably, the acidifying step is achieved by adding hydrochloric acid.
Preferably, about 1.0-1.4 equivalents of about 32% (v:v) hydrochloric acid is added to induce precipitation. Most preferably, about 1.1 equivalents of about 32%) (v:v) hydrochloric acid is added to induce precipitation. More preferably, the acidifying step is achieved at a pH about 1 to about 4. Most preferably, the acidifying step is achieved at a pH about 3.
Preferably, the washing step is achieved by using isopropanol. Preferably, about 5 to about 15ml of isopropanol is used to wash the precipitates. Most preferably, about 10 ml of isopropanol is used to wash the precipitates.
Preferably, the crystallizing step is achieved by adding about 3 to about 5 volumes of water to induce crystallization. Most preferably, about 4 volumes of water is used to induce crystallization.
Preferably, the crystallizing step is performed in the presence of activated carbon. Preferably, the activated carbon is selected from the group consisting of SX-2, CA-1, CXV, and SX-1.
Preferably, the crystallizing step is performed in the presence of about 5 to about 15% SX-1 activated carbon. Most preferably, the crystallizing step is performed in the presence of about 10% SX-1 activated carbon.
The present invention is further explained by the following examples. The present invention is by no means restricted to these specific examples. One of ordinary skill in the art will understand how to vary the exemplified preparations to obtain the desired results.
EXAMPLES
Example 1 : Preparation of Pure Dimethylamino- Methyl-Carbazolone Salt
Into 180 ml glacial acetic acid 45 gram (0.226 mole, 1.0 eq) of methyl- carbazolone, 22.4 gram ( 0.275 mole, 1.22 eq) of dimethylamine hydrochloride and 9 gram (0.3 mole, 1.33 eq) of paraformaldehyde were added.
The reaction was kept at about 80 ± 2°C during 12 hours, then 540 ml of water and 4.5 gram of highflow are introduced into the reactor, the batch was cooled to about 10°C and rendered basic with about 45% NaOH to about pH 13 to about 14 while the batch temperature did not exceed about 25°C.
Then the batch was stirred at about 5 to about 10° C for an additional 1 hour, the precipitate that formed along with the highflow were collected and dried in vacuum oven at about 60°C until constant weight to obtain crude product containing highflow.
The crude product was treated with 3.3 gram activated carbon type SX-1 (by NORIT) in 990 ml acetone, filtered, cooled to about 25°C and hydrochloric acid was bubbled through the acetone solution until pH was about 3, the batch was cooled to about 0 to about 5° C, kept at this temperature for half an hour, filtered, washed with about 20 ml acetone and dried in an oven at about 50°C until constant weight to give 49.6 gram dimethylamino-methyl-carbozolone-HCl.
Example 2: Preparation of Pure Ondansetron Base
Into 330 ml water 33 gram (0.112 mole, 1 eq.) dimethylamino-methyl- carbozolone-HCl, 3.3 gram highflow, 46.3 gram (0.563 mole, 5 eq) methyl- imidazole were added. The reaction was heated at reflux during 12 hours and cooled to about 5 to about 10° C, the precipitate was filtered, washed with 3 x 300ml water and dried in a vacuum oven at about 60° C until constant weight to give crude compound containing highflow. The crude compound was treated with 1.5 gram activated carbon type SX-
1 (by NORIT) in 930 ml methanol, filtered (hot filtration) from the highflow and activated carbon and crystallized at 0 to about 5°C during one hour. Hot filtration was around 60°C and was done with methanol near its boiling point (i.e., 65°C). The precipitate was collected by filtration, washed with 2 x 20 ml cold methanol and dried in vacuum oven at about 60°C until constant weight to give 21.3 gram ondansetron-base.
Example 3: Preparation of Pure Ondansetron Hydrochloride Dihydrate
Into 100 ml of water 20 gram ondansetron-base were introduced. To the stirred suspension 7.5 ml (1.1 equivalents) of about 32% hydrochloric acid (HCl) was added. A slightly exothermic reaction occurred, the suspension turned almost clear and a precipitate began to form.
The reaction was cooled down and kept at about 3-5°C for an additional 1 hour filtered, washed, with about 10 ml cold isopropanol and dried at about 50°C under vacuum.
Example 4: Recrystallization of Ondansetron Hydrochloride Dihydrate
Ondansetron-HCl-2H2O was crystallized twice from 1 :4 w/v water and about 10% w/w activated carbon type SX-1 (by NORIT) at about 95°C during half an hour, filtered (hot filtration), washed with 1 volume of hot water, cooled to about 5°C and kept at this temperature for about 1 hour. The crystals was collected, washed with about 10 ml cold isopropanol and dried to give pure ondansetron-HCl-2H O. The obtained pure ondansetron hydrochloride dihydrate was determined by HPLC to be at least greater than 99.0%. The obtained pure ondansetron hydrochloride dihydrate contained less than 0.01% exo-methylene byproduct or undetectable.

Claims

WHAT IS CLAIMED IS:
1. Ondansetron hydrochloride dihydrate having a purity of at least 99.0%.
2. Ondansetron hydrochloride dihydrate having a purity of at least 99.5%.
3. Ondansetron hydrochloride dihydrate having a purity of at least 99.9%.
4. A process for preparing dimethylamino-methyl-carbazolone comprising the steps of: 1.0 a) preparing a solution of methyl-carbazolone having the formula:
(where R = Cι-4, alkyl)
15
b) heating the solution in the presence of dimethylamine hydrochloride and paraformaldehyde; 0 c) basifying the solution to form a precipitate; d) separating the precipitate from the solution; e) drying the precipitate.
5. The process according to claim 4, wherein R is methyl. 5
6. The process according to claim 4, wherein the heating step is performed at a temperature of about 70°C to about 100°C.
7. The process according to claim 4, wherein the heating step is performed at 30 a temperature of about 80°C to about 90°C.
8. The process according to claim 4, wherein the heating step is performed for about 6 to about 24 hours.
35 9. The process according to claim 4, wherein the heating step is performed for about 6 to about 12 hours.
10. The process according to claim 4, wherein the heating step is performed in acetic acid.
11. The process according to claim 4, wherein about one equivalent methyl- carbazolone is heated in the presence of about 1.1 to about 1.5 equivalents of dimethylamine hydrochloride and paraformaldehyde.
12. The process according to claim 4, wherein about one equivalent methyl- carbazolone is heated in the presence of about 1.2 equivalents of dimethylamine hydrochloride and formaldehyde.
13. The process according to claim 4, wherein about one equivalent methyl- carbazolone is heated in the presence of about 1.1 to about 1.5 equivalents of dimethylamine hydrochloride and formaldehyde.
14. The process according to claim 4, wherein about one equivalent methyl- carbazolone is heated in the presence of about 1.2 equivalents of dimethylamine hydrochloride and formaldehyde.
15. The process according to claim 4, wherein about one equivalent methyl- carbazolone is heated in the presence of about 4 to about 6 volumes of acetic acid.
16. The process according to claim 4, wherein about one equivalent methyl- carbazolone is heated in the presence of about 4 volumes of acetic acid.
17. The process according to claim 4, wherein the solution of methyl- carbazolone is basified by about 45% sodium hydroxide.
18. The process according to claim 17, wherein the solution is basified to a pH of about 13 to about 14.
19. The process according to claim 17 or 18, wherein the basifying step is performed in the presence of 10% celite.
20. A process for preparing ondansetron base, comprising the steps of: a) preparing a solution of methyl-imidazole and dimethylamino-methyl- carbazolone of the formula
. HCl (where R = Cr4> alkyl)
b) heating the solution; c) removing a precipitate containing ondasetron base from the solution; washing the precipitate; e) drying precipitate to obtain ondansetron base.
21. The process according to claim 20, wherein the solution is prepared by adding about 4 to about 6 equivalents methyl-imidazole to one equivalent dimethylamino-methyl-carbazolone.
22. The process according to claim 20, wherein the solution is prepared by adding about 5 equivalents methyl-imidazole to one equivalent dimethylamino-methyl-carbazolone.
23. The process according to claim 20, wherein the solution is prepared in the presence of 10% celite.
24. The process according to claim 20, further comprising the step of: recrystallizing ondansetron base.
25. The process according to claim 24, wherein the recrystallizing step is performed in the presence of activated carbon and methanol.
26. A process of preparing pure ondansetron hydrochloride dihydrate comprising the steps of: a) preparing a solution of ondansetron base; b) acidifying the solution with hydrogen chloride to form a precipitate; c) washing the precipitate; and d) crystallizing pure ondansetron hydrochloride dihydrate.
27. The process according to claim 26 wherein about 3 to about 7 volumes of water is added to ondansetron base to prepare a solution of ondansetron base.
28. The process according to claim 26 wherein about 5 volumes of water is added to ondansetron base to prepare a solution of ondansetron base.
29. The process according to claim 26 wherein about 1.0 to about 1.4 equivalents of about 32% (v:v) hydrochloric acid is added to acidify the solution to induce precipitation.
30. The process according to claim 26 wherein about 1.1 equivalents of about 32%) (v:v) hydrochloric acid is added to acidify the solution to induce precipitation.
31. The process of claims 29 or 30, wherein the solution is acidified to a pH about 1 to about 4.
32. The process of claims 29 or 30, wherein the solution is acidified to a pH about 3.
33. The process according to claim 26, wherein the precipitate is washed with about 5 to about 15 ml of isopropanol.
34. The process according to claim 26, wherein the precipitate is washed with about 10 ml of isopropanol.
35. The process according to claim 26, wherein the crystallizing step is achieved by adding about 3 to about 5 volumes of water to induce crystallization.
36. The process according to claim 26, wherein the crystallizing step is achieved by adding about 4 volumes of water to induce crystallization.
37. The process according to claim 26, wherein the crystallization step is repeated two times.
38. The process according to claim 26, wherein the crystallizing step is achieved in the presence of activated carbon.
39. The process according to claim 36, wherein the activated carbon is selected from the group consisting of SX-2, CA-1, CXV and SX-1.
40. The process according to claim 39, wherein the activated carbon is about 5 to about 15% SX-1.
41. The process according to claim 39, wherein the activated carbon is about 5 to about 10% SX-1.
42. Ondansetron hydrochloride dihydrate as prepared in accordance with a process of claim 26, wherein the ondansetron hydrochloride dihydrate has a purity of at least about 99.0%).
43. Ondansetron hydrochloride dihydrate as prepared in accordance with a process of claim 26, wherein the ondansetron hydrochloride dihydrate have a purity of at least about 99.5%.
44. Ondansetron hydrochloride dihydrate as prepared in accordance with a process of claim 26, wherein the ondansetron hydrochloride dihydrate has a purity of at least about 99.9%.
45. A pharmaceutical formulation comprising ondansetron hydrochloride dihydrate as prepared in accordance with a process of claim 26, wherein the ondansetron hydrochloride dihydrate has a purity of at least about 99.0%.
46. A pharmaceutical formulation comprising ondansetron hydrochloride dihydrate as prepared in accordance with a process of claim 26, wherein the ondansetron hydrochloride dihydrate has a purity of at least about 99.5%.
47. A pharmaceutical formulation comprising ondansetron hydrochloride dihydrate as prepared in accordance with a process of claim 26, wherein the ondansetron hydrochloride dihydrate has a purity of at least about 99.9%.
EP02703115A 2001-01-11 2002-01-11 An improved process for preparing pure ondansetron hydrochloride dihydrate Withdrawn EP1355881A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26105201P 2001-01-11 2001-01-11
US261052P 2001-01-11
PCT/US2002/000853 WO2002055492A2 (en) 2001-01-11 2002-01-11 An improved process for preparing pure ondansetron hydrochloride dihydrate

Publications (2)

Publication Number Publication Date
EP1355881A2 true EP1355881A2 (en) 2003-10-29
EP1355881A4 EP1355881A4 (en) 2004-03-31

Family

ID=22991757

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02703115A Withdrawn EP1355881A4 (en) 2001-01-11 2002-01-11 An improved process for preparing pure ondansetron hydrochloride dihydrate

Country Status (21)

Country Link
EP (1) EP1355881A4 (en)
JP (1) JP2004526692A (en)
KR (3) KR20060113792A (en)
CN (2) CN1496350A (en)
AU (1) AU2002236753B2 (en)
CA (1) CA2433720A1 (en)
CZ (1) CZ20032090A3 (en)
DE (1) DE02703115T1 (en)
ES (1) ES2219201T1 (en)
HR (1) HRP20030631A2 (en)
HU (1) HUP0400767A2 (en)
IL (1) IL156835A0 (en)
IS (1) IS6869A (en)
MX (1) MXPA03006215A (en)
NO (1) NO20033147L (en)
PL (1) PL368837A1 (en)
SK (1) SK9892003A3 (en)
TR (1) TR200401460T3 (en)
WO (1) WO2002055492A2 (en)
YU (1) YU56103A (en)
ZA (1) ZA200305338B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7098345B2 (en) 2002-04-29 2006-08-29 TEVA Gyógyszergyár Zárkörüen Müködö Részvénytársaság Process for preparing 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-YL)methyl]-4H-carbazol-4-one
HU225885B1 (en) * 2002-10-17 2007-11-28 Richter Gedeon Nyrt Process for producing ondansetron hydrochlorid dihydrate of high purity
FI6164U1 (en) * 2003-01-09 2004-03-15 Synthon Bv Ondansetronformer
GB2398071B (en) * 2003-01-24 2006-06-07 Synthon Bv Process for making ondansetron and intermediate thereof
US7696356B2 (en) 2004-08-17 2010-04-13 Taro Pharmaceutical Industries Limited Process for preparing 1,2,3,9-tetrahydro-9-methyl-3-methylene-4H-carbazol-4-one and ondansetron therefrom
EP1828141A4 (en) * 2004-10-26 2009-04-01 Ipca Lab Ltd A one-pot process for the preparation of antiemetic agent, 1,2,3,9-tetrahydro-9-methyl-3[(2-methyl)-1h-imidazole-1-yl)methyl]-4h-carbazol-4-o

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002036558A2 (en) * 2000-10-30 2002-05-10 Teva Pharmaceutical Industries Ltd. Novel crystal and solvate forms of ondansetron hydrochloride and processes for their preparation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4695578A (en) * 1984-01-25 1987-09-22 Glaxo Group Limited 1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances
GB8630071D0 (en) * 1986-12-17 1987-01-28 Glaxo Group Ltd Medicaments

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002036558A2 (en) * 2000-10-30 2002-05-10 Teva Pharmaceutical Industries Ltd. Novel crystal and solvate forms of ondansetron hydrochloride and processes for their preparation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO02055492A2 *

Also Published As

Publication number Publication date
CN101045704A (en) 2007-10-03
NO20033147D0 (en) 2003-07-09
WO2002055492A2 (en) 2002-07-18
CZ20032090A3 (en) 2004-08-18
PL368837A1 (en) 2005-04-04
EP1355881A4 (en) 2004-03-31
NO20033147L (en) 2003-09-02
MXPA03006215A (en) 2005-02-17
HRP20030631A2 (en) 2005-06-30
AU2002236753B2 (en) 2007-06-28
YU56103A (en) 2006-05-25
IL156835A0 (en) 2004-02-08
IS6869A (en) 2003-07-08
KR20030068583A (en) 2003-08-21
KR20070054749A (en) 2007-05-29
CN1496350A (en) 2004-05-12
JP2004526692A (en) 2004-09-02
HUP0400767A2 (en) 2004-07-28
TR200401460T3 (en) 2004-08-23
ZA200305338B (en) 2004-07-12
CA2433720A1 (en) 2002-07-18
SK9892003A3 (en) 2004-05-04
WO2002055492A3 (en) 2003-02-13
KR20060113792A (en) 2006-11-02
ES2219201T1 (en) 2004-12-01
DE02703115T1 (en) 2004-10-21

Similar Documents

Publication Publication Date Title
AU2021202576B2 (en) Fenfluramine compositions and methods of preparing the same
CN105061414B (en) One kettle way prepares Brexpiprazole
CA2942301A1 (en) Clomiphene synthesis using a single solvent
CN111630049B (en) Process for preparing 2- (5-methoxyisochroman-1-yl) -4, 5-dihydro-1H-imidazole and bisulphates thereof
US20020143211A1 (en) Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochlorid, processes for preparing thereof
US9428442B2 (en) Process for the preparation of Clomiphene
HU228204B1 (en) New process for the preparation of 11-amino-3-chloro-6,11-dihydro-5,5-dioxo-6-methyl-dibenzo[c,f][1,2]thiazepine and use thereof for the synthesis of tianeptine
JP2008511684A (en) Purification method for anastrozole intermediate
JP2005507900A (en) Citalopram manufacturing method
AU2002236753B2 (en) An improved process for preparing pure ondansetron hydrochloride dihydrate
AU2002236753A1 (en) An improved process for preparing pure ondansetron hydrochloride dihydrate
US20020115707A1 (en) Process for preparing pure ondansetron hydrochloride dihydrate
TWI291956B (en) Improved process
US20100063299A1 (en) Process for Preparing Irbesartan
CN112142604A (en) Preparation method of bromhexine hydrochloride and intermediate thereof
EP3015454A1 (en) Stable solid form of trans-Clomiphene citrate
EP2072510A1 (en) Crystalline form of azelastine
WO2003007872A2 (en) Process for the preparation of citalopram hydrobromide
KR100342919B1 (en) A preparation and purification for trans isomer of tramadol hydrochloride
WO1991017973A1 (en) 5H-DIBENZO(a,d)CYCLOHEPTENES AS MUSCARINIC RECEPTOR ANTAGONISTS
CN110885315A (en) Preparation method of important intermediate of levosimendan
CN113354652A (en) Synthesis method of nalmefene hydrochloride
EP3759081A1 (en) An improved process for the preparation of propiomazine maleate
KR810000817B1 (en) Process for preparing n,n-dimethyl-3-(4-bromophenyl)-3(3-pyridine)-arylamine
WO2002048120A1 (en) Novel crystals of oxazepine derivatives and process for the production thereof

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030804

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20040212

RIC1 Information provided on ipc code assigned before grant

Ipc: 7C 07D 209/88 A

REG Reference to a national code

Ref country code: GR

Ref legal event code: PP

Ref document number: 20040300023

Country of ref document: GR

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRCL

TCAT At: translation of patent claims filed
TCNL Nl: translation of patent claims filed
DET De: translation of patent claims
EL Fr: translation of claims filed
17Q First examination report despatched

Effective date: 20050614

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1056167

Country of ref document: HK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100803